A clinical-stage biotechnology company developing novel gene therapies that have the potential to improve and protect the lives of patients by enhancing their immune systems. Calimmune’s initial disease target is HIV/AIDS.
Calimmune has successfully completed a $15 million Series B financing round, led by a large pharmaceutical strategic investor. Alexandria Venture Investments also participated, joining existing investors including RA Capital Healthcare Fund LP and Translational Accelerator LLC. Read more
Calimmune’s new website will launch soon. Thank you for your patience.